For a patient with ADRA2A C/C (moderately reduced response to ADHD medications), HLA‑A*3101 A/A and HLA‑B*1502 absent (normal risk for severe cutaneous adverse reactions), HTR2A G/G (increased sensitivity to paroxetine), SLC6A4 L/S (intermediate response to SSRIs), CES1A1 normal activity, CYP1A2 C/A genotype (activity dependent on smoking status), CYP2B6 *1/*6 intermediate metabolizer, CYP2C19 *1/*1 extensive metabolizer, CYP2C9 *1/*1 extensive metabolizer, CYP2D6 *2/*4 intermediate metabolizer, CYP3A4 *1/*1 extensive metabolizer, UGT1A4 *1/*1 extensive metabolizer, UGT2B15 *1/*2 intermediate metabolizer, and no MTHFR variant, what are the recommended medication choices and dosing for ADHD, depression/anxiety, and mood stabilization?

Pharmacogenomic-Guided Medication Recommendations

Based on this patient's genetic profile, avoid paroxetine entirely due to HTR2A G/G genotype (increased adverse reaction risk), use alternative SSRIs with caution due to CYP2D6 intermediate metabolizer status and SLC6A4 L/S genotype, consider non-stimulant ADHD medications given ADRA2A C/C genotype, and adjust dosing for all CYP2D6-metabolized drugs downward by approximately 25-50%. 1

ADHD Treatment Strategy

Primary Consideration: ADRA2A C/C Genotype

Your patient carries the ADRA2A C/C genotype, which suggests moderately reduced response to methylphenidate specifically 2. While meta-analysis shows G-allele carriers have 3-fold better odds of symptom improvement with methylphenidate (OR 3.08,95% CI 1.71-5.56), your patient lacks this favorable allele 2.

Recommended ADHD Medication Hierarchy:

First-line options:

• Atomoxetine - BUT requires significant dose reduction (start at 50% of standard dose) due to CYP2D6 *2/*4 intermediate metabolizer status 1, 3. The FDA label explicitly states atomoxetine exposure increases 6-8 fold when combined with CYP2D6 inhibitors; intermediate metabolizers experience intermediate elevation 1.
• Guanfacine or clonidine (alpha-2 agonists) - These are FDA-approved nonstimulants not affected by your patient's pharmacogenetic profile 4, 5.

Second-line options:

• Amphetamine preparations - Not significantly affected by ADRA2A genotype; metabolism primarily through CYP2D6 but less dependent than atomoxetine 3.
• Methylphenidate - Can be used but expect reduced efficacy; CES1A1 GLY/GLY indicates normal carboxylesterase activity, so standard dosing applies if chosen 3.

Critical dosing note for atomoxetine: Start at 0.25 mg/kg/day (rather than standard 0.5 mg/kg/day), titrate slowly over 4-6 weeks, and monitor closely for adverse effects including cardiovascular effects and hepatotoxicity 1, 3.

Depression/Anxiety Treatment Strategy

Paroxetine: CONTRAINDICATED

Do not prescribe paroxetine. Your patient's HTR2A G/G genotype confers increased sensitivity to paroxetine-related adverse reactions 1, 6, 7. The G/G genotype at the -1438G>A polymorphism is associated with heightened risk of side effects and poor tolerability 7.

SLC6A4 L/S Genotype Impact

The heterozygous short/long promoter polymorphism predicts intermediate SSRI response - better than S/S homozygotes but not as robust as L/L carriers 6, 8. This suggests SSRIs will work but may require:

• Longer titration periods (8-12 weeks rather than 4-6 weeks)
• Potentially higher doses within therapeutic range
• Greater attention to early side effects that might predict non-response

CYP2D6 *2/*4 Intermediate Metabolizer Implications

Your patient metabolizes CYP2D6 substrates at approximately 50% normal capacity 6, 9. This affects multiple antidepressants:

Avoid or use extreme caution:

• Fluoxetine - CYP2D6 substrate; intermediate metabolizers have 2-3 fold higher exposure
• Paroxetine - Already contraindicated for HTR2A reasons; also CYP2D6 substrate
• Venlafaxine - Conversion to active metabolite desvenlafaxine impaired; reduced efficacy expected

Preferred SSRI/SNRI options with dose adjustments:

1. Sertraline - First choice

   • Start: 25 mg daily (rather than 50 mg)
   • Target: 50-100 mg daily (rather than 100-200 mg)
   • Partially metabolized by CYP2D6 but has multiple pathways
   • Monitor for side effects but generally well-tolerated in intermediate metabolizers 6, 8

2. Escitalopram - Second choice

   • Start: 5 mg daily (rather than 10 mg)
   • Target: 10-15 mg daily (rather than 20 mg)
   • Primarily CYP2C19 (your patient is *1/*1 extensive metabolizer - favorable)
   • Minor CYP2D6 involvement 6, 9

3. Citalopram - Third choice

   • Start: 10 mg daily (rather than 20 mg)
   • Target: 20-30 mg daily (rather than 40 mg)
   • Similar profile to escitalopram
   • Watch QTc prolongation at higher doses 6

Alternative non-SSRI options:

• Bupropion - Excellent choice; not serotonergic, avoiding HTR2A and SLC6A4 concerns

  • CYP2B6 *1/*6 intermediate metabolizer status: start standard dose (150 mg SR daily), may need 25% dose reduction if side effects emerge
  • Particularly useful if comorbid ADHD symptoms persist 6

• Mirtazapine - Not significantly affected by patient's genetic profile; standard dosing (15-45 mg nightly) 6

Mood Stabilizer Considerations

HLA Alleles: Normal Risk Profile

Your patient's HLA-A3101 A/A and absent HLA-B1502 indicate normal risk for severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) with carbamazepine, oxcarbazepine, and lamotrigine 10. Standard prescribing applies without need for alternative agents based on hypersensitivity risk.

If mood stabilization needed:

• Lamotrigine - Safe to use; standard titration schedule (25 mg daily × 2 weeks, then 50 mg daily × 2 weeks, then increase by 50 mg every 1-2 weeks to target 200-400 mg daily)
• Valproate - Not affected by patient's genetic profile; standard dosing
• Lithium - Not affected by patient's genetic profile; standard dosing with therapeutic monitoring

Smoking Status Modifier

CYP1A2 C/A Genotype

If patient is a non-smoker: Extensive (normal) metabolizer phenotype - standard dosing for CYP1A2 substrates (e.g., duloxetine, mirtazapine, some antipsychotics)

If patient is a smoker: Ultrarapid metabolizer phenotype - may require 50-100% dose increases for CYP1A2 substrates due to highly inducible A allele 3

Practical Implementation Algorithm

Step 1: ADHD Treatment

• Start guanfacine 1 mg daily, titrate to 2-4 mg over 4 weeks
• OR start atomoxetine 0.25 mg/kg/day (max 40 mg), titrate to 0.8 mg/kg/day over 6-8 weeks
• Avoid methylphenidate as first-line due to ADRA2A C/C

Step 2: Depression/Anxiety Treatment

• Start sertraline 25 mg daily, increase to 50 mg after 1 week, target 50-100 mg
• OR start bupropion SR 150 mg daily, increase to 150 mg BID after 1 week
• Monitor for 8-12 weeks before declaring treatment failure (SLC6A4 L/S predicts slower response)

Step 3: Monitoring

• Baseline: ECG (if using sertraline/escitalopram), liver function tests, blood pressure
• Week 2: Side effect assessment, adherence check
• Week 4: Symptom rating scales, vital signs
• Week 8: Full response assessment
• Week 12: Decision point for dose optimization or medication switch

Critical Pitfalls to Avoid

1. Do not use standard atomoxetine dosing - This is the single highest-risk medication for your patient given CYP2D6 intermediate metabolizer status; overdosing is likely with standard protocols 1, 3

2. Do not prescribe paroxetine under any circumstances - HTR2A G/G genotype creates unacceptable adverse reaction risk 1, 7

3. Do not expect rapid SSRI response - SLC6A4 L/S genotype predicts 8-12 week timeline rather than 4-6 weeks 6, 8

4. Do not combine atomoxetine with any SSRI - The FDA label explicitly warns that paroxetine increases atomoxetine exposure 6-8 fold; even with non-paroxetine SSRIs, your patient's CYP2D6 intermediate status creates additive risk 1

5. Do not assume methylphenidate will work well - ADRA2A C/C genotype predicts 3-fold lower odds of response compared to G-allele carriers 2